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Abstract
In this report we test the hypothesis that long-term virus-induced alterations in CYP occur from
changes initiated by the virus that may not be related to the immune response. Enzyme activity,
protein expression and mRNA of CYP3A2, a correlate of human CYP3A4, and CYP2C11,
responsive to inflammatory mediators, were assessed 0.25, 1, 4, and 14 days after administration
of several different recombinant adenoviruses at a dose of 5.7 × 1012 virus particles (vp)/kg to male
Sprague Dawley rats. Wild type adenovirus, containing all viral genes, suppressed CYP3A2 and
2C11 activity by 37% and 39%, respectively within six hours. Levels fell to 67% (CYP3A2) and 79%
(CYP2C11) of control by 14 days (p ≤ 0.01). Helper-dependent adenovirus, with all viral genes
removed, suppressed CYP3A2 (43%) and CYP2C11 (55%) within six hours. CYP3A2 remained
significantly suppressed (47%, 14 days, p ≤ 0.01) while CYP2C11 returned to baseline at this time.
CYP3A2 and 2C11 were reduced by 45 and 42% respectively 6 hours after treatment with
PEGylated adenovirus, which has a low immunological profile (p  ≤ 0.05). CYP3A2 remained
suppressed (34%, p ≤ 0.05) for 14 days while CYP2C11 recovered. Inactivated virus suppressed
CYP3A2 activity by 25–50% for 14 days (p ≤ 0.05). CYP2C11 was affected similar manner but
recovered by day 14. Microarray and in vitro studies suggest that changes in cellular signaling
pathways initiated early in virus infection contribute to changes in CYP.
Introduction
Hepatic cytochrome P450 (CYP) enzymes play a central
role in the metabolism and clearance of many naturally
occurring biological substances, drugs and environmental
toxins [1,2]. In turn, their diversity, expression and func-
tion may also be modified by these substrates [3,4].
Numerous clinical reports have also described altered
pharmacokinetic and toxicity profiles of drugs during
infection or inflammation [5,6]. In these instances, the
activity and expression of CYP is downregulated, leading
to ineffective treatment regimens, unexpected adverse
reactions and in, some cases, drug-drug interactions [7,8].
Similar effects have been reported with respect to the
expression and function of CYP isforms 3A2 and 2C11
after a single dose of recombinant adenovirus serotype 5
for a period of 14 days in the male Sprague Dawley rat
[9,10]. The expression and function of these isoforms,
selected for their predominance in drug metabolism
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(CYP3A2) and their responsiveness to inflammatory stim-
uli (CYP2C11), are largely influenced by the dose (5.7 ×
106 – 5.7 × 1012 viral particles/kilogram (vp/kg)) and the
nature of the transgene cassette. Although much is known
about the regulatory processes associated with CYP3A2
and 2C11 expression, the exact mechanism by which virus
infection alters these metabolic enzymes is currently
unknown.
Recombinant adenoviruses were chosen as model patho-
gens to further define processes by which viral infection
alters expression of CYP3A2 and 2C11 for several reasons.
Although wild type adenovirus infections are common in
the general population and often cause self-limited respi-
ratory infections, they also induce significant illness and
high mortality in specialized patient populations such as
those receiving allogenic stem cell and solid organ trans-
plants and those with acute respiratory illnesses [11-14].
Within the last decade, extensive use of adenovirus sero-
type 5 as a vector for gene therapy and vaccine develop-
ment has increased understanding of the biology and the
genetic features of the virus. This information has fostered
the production of a series of recombinant viruses with
minimal viral elements to reduce the host immune
response and extend the length of gene expression
achieved by this otherwise highly efficient vector. In this
report, a panel of recombinant adenoviruses were studied
in a Sprague Dawley rat model to test the hypothesis that
changes in hepatic CYP expression and function after a
single systemic dose of virus may not be solely due to the
immune response against viral gene products and capsid
proteins. Wild type adenovirus serotype 5, capable of
causing mild illness in the general public and more severe
complications in the immunosuppressed and those with
asthma and COPD, was used as a positive control. It con-
tained all virus expression elements. A first generation
adenoviral vector, expressing the E. coli beta-galactosidase
transgene (AdlacZ) was included as an important control
for direct comparison of results previously reported to
those obtained from animals treated with the other mod-
ified vectors [9,10]. The early region 1 (E1, involved in
virus replication) and early region 3 (E3, involved in eva-
sion of the host immune response) parts of the virus
genome were removed in this vector to accommodate the
beta-galactosidase transgene cassette. A PEGylated version
of this virus, which has a significantly lower immunolog-
ical profile [15,16], and an inactive control, AdlacZ inac-
tivated by exposure to riboflavin and UV light, were
included to study the effect of the immune response
against virus capsid proteins and virus receptor interac-
tions on expression and function of CYP. A helper-
dependent adenoviral vector (HDAd), devoid of all viral
genes and containing the E. coli beta-galactosidase trans-
gene, was also included to fully study the effect of viral
gene expression on CYP. CYP protein expression, activity,
and mRNA were evaluated at 0.25, 1, 4 and 14 days, a
time course highlighting key points during adenoviral
gene expression and the host immune response [17].
Serum alanine amintotransferase levels and histological
evaluation of liver tissue were used to evaluate the toxicity
associated with administration of each vector. Expression
patterns of the pregnane × receptor (PXR) and the retinoid
× receptor alpha (RXR∝), involved in transcriptional reg-
ulation of CYP [18,19], and those associated with several
signal transduction pathways in the liver are also dis-
cussed.
Results
Effect of administration of recombinant adenoviruses on 
hepatic CYP3A2 expression and function
Hepatic CYP3A2 protein expression, catalytic activity, and
mRNA levels were analyzed at 0.25, 1, 4, and 14 days after
administration of either wild type virus or several different
recombinant adenoviruses. Six hours after administra-
tion, each virus significantly suppressed CYP3A1/2 pro-
tein (Figure 1A). The most pronounced effect was
observed in samples obtained from animals given wild
type (WT) virus with protein levels 46% of those seen in
saline treated animals (Vehicle, p ≤ 0.01). Inactivated virus
(UVAd) affected CYP3A1/2 protein the least (19% of con-
trol, p ≤ 0.01). Twenty-four hours after treatment, protein
levels of these animals returned to baseline and remained
so for the duration of the study (Figure 1B). At this time,
the other vectors reduced CYP3A1/2 by approximately
50% (p ≤ 0.01). Four days after treatment, CYP3A1/2 was
still markedly suppressed in animals given WT virus, 65%
of control, but levels began to recover in animals given the
other viruses. Protein expression levels were 36%, 32%,
and 39% of control for animals given AdlacZ, PEGAd, and
HDAd, respectively at this timepoint (Figure 1C, p ≤ 0.01).
Fourteen days after administration CYP3A1/2 protein
remained significantly suppressed without evidence of
recovery in animals treated with WT (31% of control)
AdlacZ (37%) and HDAd (29%) (Figure 1D, p ≤ 0.01).
CYP3A2 activity was assessed by separation and quantifi-
cation of the isoform-specific primary testosterone metab-
olite, 6β-hydroxytestosterone. Each virus significantly
reduced CYP3A2 activity throughout the entire duration
of the study (Figure 2). Six hours after administration,
CYP3A2 activity was suppressed by approximately 41%,
in each treatment group with respect to that of saline
treated animals (Figure 2A, p ≤ 0.01). Twenty-four hours
after administration, the most significant suppression was
seen in samples obtained from animals treated with
PEGAd, 72% of control, and HDAd, 67% (p ≤ 0.01). Both
WT and AdlacZ treated animals experienced a notable
reduction in metabolic activity, approximately 45%.
CYP3A2 activity was reduced by 20% in animals given the
UVAd vector at the same timepoint (Figure 2B, p ≤ 0.01).Virology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
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In a manner similar to protein expression, the wild-type
virus induced the most significant suppression of CYP3A2
activity four days after administration. Animals given this
virus had activity levels that were 67% of that found in
saline treated animals (Figure 2C, p ≤ 0.01). CYP3A2 activ-
ity for both AdlacZ and UVAd treated animals were simi-
lar to that seen at 24 hours, 46% and 24% of control,
respectively. At the same timepoint, activity levels for ani-
mals given either PEGAd or HDAd began to recover to
baseline levels. Fourteen days after a single dose of virus,
CYP3A2 activity continued to be reduced in each treat-
ment group. Treatment with WT, AdlacZ, PEGAd, HDAd,
and UVAd, resulted in activity that was 58%, 32%, 26%,
49%, and 31% of saline treated animals respectively (Fig-
ure 2D, p ≤ 0.05).
Administration of active viruses also significantly reduced
hepatic CYP3A2 mRNA as early as six hours after admin-
istration. Treatment with WT and AdlacZ reduced mRNA
levels by 31% and 24% respectively (Figure 3A, p ≤ 0.01).
Administration of a Single Dose of Active Adenovirus Significantly Suppresses Hepatic CYP3A1/2 Protein Expression for 14  Days without Recovery Figure 1
Administration of a Single Dose of Active Adenovirus Significantly Suppresses Hepatic CYP3A1/2 Protein 
Expression for 14 Days without Recovery. Immunoblot analysis and representative immunoblots of hepatic CYP3A1/2 
protein expression 0.25 (A), 1 (B), 4 (C), and 14 (D) days after a single intravenous dose of wild type adenovirus serotype 5 
(WT), a first generation recombinant adenovirus serotype 5 expressing E. coli beta-galactosidase (AdlacZ), PEGylated AdlacZ, 
(PEGAd), helper-dependent adenovirus serotype 5 expressing beta-galactosidase (HDAd), or inactivated AdlacZ (UVAd) in 
male Sprague-Dawley rats. Protein levels are reported as the relative density of positive bands with respect to that of a known 
protein standard in arbitrary units. Values are presented as the mean ± standard error of 4 animals/treatment/timepoint. Statis-
tical significance was determined between individual treatment groups and vehicle controls by one-way analysis of variance 
with a Bonferroni/Dunn post-hoc analysis. *p ≤ 0.05, **p ≤ 0.01.Virology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
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CYP3A2 mRNA levels of animals treated with the wild-
type virus were consistently suppressed throughout the
duration of the study. They were reduced by 42%, 40%
and 41% after 24 hours, 4, and 14 days (Figure 3B, C, and
3D, p ≤ 0.01). Contrary to these findings, the UV inacti-
vated virus did not alter CYP3A2 mRNA. Twenty-four
hours after administration, mRNA levels in the AdlacZ
and PEGAd treatment groups were approximately 30%
below those of saline treated animals (Figure 3B, p  ≤
0.01). At the four-day timepoint, mRNA levels remained
suppressed in the PEGAd treated animals (29% of con-
trol). mRNA was reduced in a similar manner in animals
treated with HDAd (30% of control, Figure 3C, p ≤ 0.01).
Fourteen days after administration, mRNA was still
reduced in animals given AdlacZ, PEGAd, and HDAd (27,
27, and 39%, of control respectively, Figure 3D, p ≤ 0.01).
Effect of a single dose of virus on hepatic CYP2C11 
expression and function
CYP2C11 protein expression was significantly suppressed
six hours after administration of the WT (37%) and
PEGAd (26%) viruses (Figure 4A, p ≤ 0.05). Twenty-two
hours later, the most profound suppression (68% of con-
trol) was seen in animals given AdlacZ (Figure 4B, p ≤
Administration of a Single Dose of Active and Inactive Adenovirus Significantly Reduces Hepatic CYP3A2 Activity in the Male  Sprague-Dawley Rat for 14 Days without Return to Baseline Levels Figure 2
Administration of a Single Dose of Active and Inactive Adenovirus Significantly Reduces Hepatic CYP3A2 
Activity in the Male Sprague-Dawley Rat for 14 Days without Return to Baseline Levels. In vitro catalytic activity of 
CYP3A2 microsomal proteins were measured by the production of the enzyme-specific testosterone metabolite, 6β-hydrox-
ytestosterone. Rats were treated with: phosphate buffered saline (Vehicle), wild type adenovirus serotype 5 (WT), a first gen-
eration recombinant adenovirus 5 expressing E. coli beta-galactosidase (AdlacZ), PEGylated AdlacZ, (PEGAd), helper-
dependent adenovirus 5 expressing beta-galactosidase (HDAd), or inactivated AdlacZ (UVAd). Values are presented as the 
mean ± standard error of 4 animals/treatment/timepoint. Statistical significance was determined between individual treatment 
groups and saline controls by one-way analysis of variance with a Bonferroni/Dunn post-hoc analysis. *p ≤ 0.05, **p ≤ 0.01.Virology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
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0.01). At this time, this isoform was also significantly
reduced by, 50, 38, 37, and 26% after treatment with WT,
PEGAd, HDAd, and UVAd, respectively. CYP2C11 protein
levels began to recover in animals treated with PEGAd,
HDAd, and UVAd four days after administration, when
they were only 14, 26, and 12% of saline treated controls
(Figure 4C, p ≤ 0.05). Protein levels continued to be mark-
edly suppressed in animals given the WT (25%) and
AdlacZ (35%) viruses fourteen days after treatment (Fig-
ure 4D, p ≤ 0.05).
Each virus included in this study also significantly affected
CYP2C11 activity, as determined by measuring the
amount of the isoform-specific metabolite of testoster-
one, 2α-hydroxytestosterone, for fourteen days (Figure
5A, B, and 5C). Six hours after treatment, CYP2C11 activ-
ity was reduced by 34% in animals treated with UVAd and
by approximately 52% in all other treatment groups (Fig-
ure 5A, p ≤ 0.01). This effect persisted at the twenty-four
hour time point when activity was 57, 50, 63, 53, and
26% of control (WT, AdlacZ, PEGAd, HDAd, and UVAd
A Single Dose of Active Virus Significantly Suppresses Hepatic CYP3A2 mRNA in Male Sprague Dawley Rats Figure 3
A Single Dose of Active Virus Significantly Suppresses Hepatic CYP3A2 mRNA in Male Sprague Dawley Rats. 
Mean relative intensities of CYP3A2 mRNA and representative agarose gels of PCR products 0.25 (A), 1 (B), 4 (C), and 14 (D) 
days after treatment with wild type adenovirus 5 (WT), first generation recombinant adenovirus expressing E. coli beta-galac-
tosidase (AdlacZ), PEGylated AdlacZ, (PEGAd), helper-dependent virus expressing beta-galactosidase (HDAd), or inactivated 
AdlacZ (UVAd). mRNA levels are reported as band densities of gene-specific RT-PCR products with respect to the density of 
products from an internal control (18S rRNA) in arbitrary units. In all panels, animals dosed with phosphate buffered saline 
served as controls (Vehicle). Values are presented as the mean ± standard error of 4 animals/treatment/timepoint. Statistical 
significance was determined between individual treatment groups and vehicle controls by one-way analysis of variance with a 
Bonferroni/Dunn post-hoc analysis. *p ≤ 0.05, **p ≤ 0.01.Virology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
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treatment groups, respectively, Figure 5B, p ≤ 0.01). Four
days after treatment, hepatic CYP2C11 activity was
reduced by 88% and 76% in animals given WT and
AdlacZ (Figure 5C, p ≤ 0.01). This effect began to improve
in animals given PEGAd (21%), HDAd (46%) and UVAd
(25%) at the same timepoint (Figure 5C, p ≤ 0.05) with
complete restoration of normal CYP2C11 activity
observed by day 14 (Figure 5D). At this timepoint, activity
levels were still approximately 40% of control in animals
given the WT and AdlacZ viruses (Figure 5D, p ≤ 0.01).
Treatment with AdlacZ and HDAd significantly reduced
CYP2C11 mRNA levels six hours after administration (33
and 25% of control respectively, Figure 6A, p ≤ 0.05).
Changes in mRNA levels at the 24-hour time point closely
mimicked that of protein expression in all treatment
groups. The most significant reduction in hepatic
CYP2C11 mRNA resulted from treatment with AdlacZ
(56%) while the WT, PEGAd and HDAd treatments
reduced mRNA by 36, 31, and 21% (Figure 6B, p ≤ 0.01).
By day four, animals treated with the WT virus experi-
A Single Dose of Adenovirus Significantly Suppresses Hepatic CYP2C11 1 and 4 Days After Administration Figure 4
A Single Dose of Adenovirus Significantly Suppresses Hepatic CYP2C11 1 and 4 Days After Administration. 
Mean hepatic CYP2C11 protein expression levels 0.25 (A), 1 (B), 4 (C), and 14 (D) days after a single dose of: phosphate buff-
ered saline (Vehicle), wild type adenovirus 5 (WT), first generation recombinant adenovirus expressing beta-galactosidase 
(AdlacZ), PEGylated AdlacZ, (PEGAd), helper-dependent adenovirus (HDAd), or inactivated virus (UVAd). Protein levels are 
reported as the relative density of positive bands with respect to that of a known protein standard in arbitrary units. Values are 
presented as the mean ± standard error of 4 animals/treatment/timepoint. Statistical significance was determined between indi-
vidual treatment groups and vehicle controls by one-way analysis of variance with a Bonferroni/Dunn post-hoc analysis, *P ≤ 
0.05 and **P ≤ 0.01.Virology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
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enced the most pronounced suppression (86%, Figure 6C,
p ≤ 0.01). At the same time, CYP2C11 mRNA was reduced
by 63% and 15% in animals given the AdlacZ and PEGAd
viruses (p ≤ 0.05). By 14 days, mRNA levels in animals
treated with PEGAd and HDAd had recovered to baseline
while those treated with WT and AdlacZ continued to be
suppressed by 29% and 18% respectively (Figure 6D, p ≤
0.01). No significant changes in CYP2C11 mRNA were
detected in animals given the inactive virus (UVAd)
throughout the course of the study.
Assessment of serum ALT after a single dose of adenovirus
A dose-dependent, self-limiting hepatotoxicity, often
indicated by transient elevation of serum transaminases,
is known to occur soon after administration of recom-
binant adenoviruses [20,21]. In an effort to monitor the
hepatotoxicity associated with each of the vectors
included in this study, serum alanine aminotransferase
(ALT) levels were assessed over 14 days. Only animals
given WT or AdlacZ experienced significant changes in
serum ALT (Figure 7). Twenty-four hours after administra-
tion, a 4-fold increase was observed in both treatment
groups (Figure 7B, p ≤ 0.01). Levels increased further by a
factor of 7 (WT) and 12 (AdlacZ) above that observed in
A Single Dose of Active and Inactive Adenovirus Significantly Affects Hepatic CYP2C11 Catalytic Activity for Four Days Figure 5
A Single Dose of Active and Inactive Adenovirus Significantly Affects Hepatic CYP2C11 Catalytic Activity for 
Four Days. In vitro catalytic activity of CYP2C11 microsomal proteins, as determined by measuring the production of the iso-
form-specific testosterone metabolite, 2α-hydroxytestosterone. Male Sprague-Dawley rats were given either: phosphate buff-
ered saline (Vehicle), wild type virus (WT), first generation recombinant virus expressing beta-galactosidase (AdlacZ), 
PEGylated AdlacZ, (PEGAd), helper-dependent virus (HDAd), or inactivated virus (UVAd). Values are presented as the mean ± 
standard error of 4 animals/treatment/time point. Statistical significance was determined between each treatment group and 
vehicle controls by one-way analysis of variance with a Bonferroni/Dunn post-hoc test. *p ≤ 0.05, **p ≤ 0.01.Virology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
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saline treated animals at the four-day time point (Figure
7C, p ≤ 0.05). Fourteen days after administration, ALT lev-
els returned to baseline in animals given the WT virus.
Levels in animals treated with AdlacZ, however, remained
elevated by a factor of 4.5 (Figure 7D, p ≤ 0.05).
Evaluation of transgene expression
Hepatic tissue isolated four days after treatment was sec-
tioned and stained histochemically to evaluate the degree
of transgene expression achieved with a single dose of
each virus (Figure 8). Approximately 95% of hepatocytes
expressed the beta-galactosidase transgene following
administration of AdlacZ and PEGAd (Figure 8B and 8C).
The HDAd vector transduced approximately 30% of all
Hepatic CYP2C11 mRNA levels are Significantly Reduced for at Least Four Days After A Single Dose of Active Adenovirus Figure 6
Hepatic CYP2C11 mRNA levels are Significantly Reduced for at Least Four Days After A Single Dose of Active 
Adenovirus. Mean relative intensities of RT-PCR products and representative agarose gels 0.25 (A), 1 (B), 4 (C), and 14 (D) 
days after treatment with wild type virus (WT), first generation recombinant adenovirus expressing beta-galactosidase 
(AdlacZ), PEGylated AdlacZ, (PEGAd), helper-dependent virus (HDAd), or inactivated AdlacZ (UVAd). mRNA levels are 
reported as band densities of gene-specific RT-PCR products with respect to the density of products from an internal control 
(18S rRNA) in arbitrary units. For all panels, animals dosed with phosphate buffered saline served as controls (Vehicle). Values 
are presented as the mean ± standard error of 4 animals/treatment/timepoint. Statistical significance was determined between 
individual treatment groups and vehicle controls by one-way analysis of variance with a Bonferroni/Dunn post-hoc analysis. *p 
≤ 0.05, **p ≤ 0.01.Virology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
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hepatocytes (Figure 8D). Complete inactivation of the
AdlacZ vector was confirmed by the absence of beta-galac-
tosidase expression in tissues isolated from animals given
UVAd. These sections stained in a manner similar to that
of saline treated animals (Figure 8E and 8A, respectively).
Mechanistic evaluation of changes in CYP during viral 
infection
The pregnane × receptor (PXR) is a key regulator of CYP3A
transcription and also contributes to CYP2C11 expression
patterns [18,19,22]. Once activated, PXR forms het-
erodimers with the retinoid × receptor alpha (RXRα). This
complex drives CYP expression. Hepatic PXR and RXRα
mRNA levels were analyzed by RT-PCR in order to deter-
mine if our observations were due to changes in the
expression of each of these key molecules during adenovi-
ral infection. Twenty-four hours after administration, PXR
levels were significantly suppressed in animals given the
WT (28%), AdlacZ (26%), PEGAd (36%), and HDAd
(33%) viruses with respect to vehicle treated controls (Fig-
ure 9B, P ≤ 0.05). Four days after treatment, PXR had
returned to baseline in all treatment groups except those
given the WT virus (30% of control, Figure 9C). PXR
expression recovered to baseline by 14 days in all treat-
Serum Transaminase Levels After A Single Dose of Adenovirus Figure 7
Serum Transaminase Levels After A Single Dose of Adenovirus. Alanine aminotransferase (ALT) levels following 
administration of: wild type adenovirus 5 (WT), first generation adenovirus expressing beta-galactosidase (AdlacZ), PEGylated 
AdlacZ, (PEGAd), helper-dependent virus expressing beta-galactosidase (HDAd), or inactivated virus (UVAd). For all panels, 
animals dosed with phosphate buffered saline served as controls (Vehicle). Values are presented as the mean ± standard error 
of 4 animals/treatment/timepoint. Statistical significance was determined between individual treatment groups and vehicle con-
trols by one-way analysis of variance with a Bonferroni/Dunn post-hoc test. *p ≤ 0.05, **p ≤ 0.01Virology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
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ment groups (Figure 9D). Significant changes in RXRα
expression were not detected in any of the treatment
groups throughout the entire study (Figure 9E–9H).
Discussion
Upsurges in Westerinization, urbanization and world
travel have sparked similar trends in the exposure rate of
the general public to infectious agents. Microbial infec-
tion can significantly compromise the expression and
function of hepatic cytochrome P450 enzymes, responsi-
ble for catalyzing biochemical processes necessary to
maintain physiological homeostasis and conversion of
medicinal agents to pharmacologically or toxicologically
active metabolites [5,6]. In vitro and in vivo studies suggest
that cytokines and other immunoresponsive molecules
associated with the acute phase of the immune response
are largely responsible for this effect. We have found that
a single dose of recombinant adenovirus significantly sup-
presses CYP3A2 and 2C11 expression and function in the
male Sprague-Dawley rat for 14 days, long after the innate
immune response against the virus resolves [9]. In an
effort to prevent corresponding increases in drug-drug
interactions, potential therapeutic failures of vital medica-
tions and secondary health problems due to interruption
of natural biochemical processes during microbial infec-
tion, the experiments described in this manuscript were
designed to determine how recombinant adenovirus
alters CYP expression and function.
None of the modifications commonly made to reduce the
immunogenicity and toxicity associated with adenoviral
vectors completely resolved aberrations in hepatic CYP.
Administration of helper-dependent adenovirus (HDAd),
devoid of all viral genes and significantly less immuno-
genic than wild type or first generation adenoviruses
[17,23], suppressed CYP3A2 protein, activity, and gene
expression for 14 days (Figures 1, 2, 3, p ≤ 0.01). Samples
obtained from animals given the PEGylated virus, which
is also significantly less immunogenic than the other
viruses tested [15,16,24,25], followed a similar trend, sug-
gesting that the immune response may not be the cause of
suppression of this key hepatic isoform. At later time-
points, CYP mRNA levels were suppressed in animals
given HDAd in a manner similar not only to the first gen-
eration virus, but to that of wild type virus, containing all
viral genetic elements, suggesting that transcription and
expression of viral genes cannot fully account for the
observed reduction of CYP3A2. Administration of the
helper-dependent and PEGylated viruses did, however,
minimize changes in the expression and function of
Hepatic Localization of Transgene Expression Four Days After a Single Dose of Adenovirus Figure 8
Hepatic Localization of Transgene Expression Four Days After a Single Dose of Adenovirus. Representative tis-
sue sections isolated from animals given (A) phosphate buffered saline (B) first generation recombinant adenovirus 5 expressing 
beta-galactosidase (AdlacZ) (C) PEGylated AdlacZ (D) helper-dependent virus expressing beta-galactosidase or (E) inactivated 
virus. Original magnification of each panel: 200 ×.Virology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
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A Single Dose of Recombinant Adenovirus Significantly Suppresses Pregnane × Receptor (PXR) mRNA in Male Sprague Dawley  Rats 24 Hours After Treatment Figure 9
A Single Dose of Recombinant Adenovirus Significantly Suppresses Pregnane × Receptor (PXR) mRNA in 
Male Sprague Dawley Rats 24 Hours After Treatment. Mean relative intensities of RT-PCR products of PXR (Panels A-
D) and the retinoid × receptor (RXR, Panels E-H) after treatment with either WT, AdlacZ, PEGAd, HDAd, or UVAd. mRNA 
levels are reported as band densities of gene-specific RT-PCR products with respect to the density of products from an inter-
nal control (18S rRNA). For all panels, animals dosed with phosphate buffered saline served as controls (Vehicle). Values are 
presented as the mean ± standard error of 4 animals/treatment/timepoint. Statistical significance was determined between indi-
vidual treatment groups and vehicle controls by one-way analysis of variance with a Bonferroni/Dunn post-hoc test. *p ≤ 0.05, 
**p ≤ 0.01.Virology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
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CYP2C11 with expression, activity, with mRNA beginning
to recover four days after administration and resolving to
baseline by day 14 (Figures 4, 5, 6, p ≤ 0.05). This and data
reported previously in which an E1/E3 deleted first gener-
ation adenovirus containing some viral gene expression
elements but not a transgene cassette and another con-
taining murine erythropoietin [10], further support the
hypothesis that changes in the expression and function of
CYP2C11 correlates with the immunogenicity of the vec-
tor and the trasngene constructs while changes in CYP3A2
may be due to shifts in cellular processes to support trans-
gene production.
Many of the vectors employed in these studies had a mild
toxicity profile with respect to serum alanine amintotrans-
ferase (ALT) levels. Only samples obtained from animals
treated with the AdlacZ and WT vectors contained signifi-
cant amounts of ALT (Figure 7). The PEGylated virus
transduced hepatocytes in a similar manner to AdlacZ
without affecting ALT, but still altered CYP expression and
function (Figures 7 and 8). Treatment with the HDAd vec-
tor also did not affect ALT, but changes in CYP were still
observed. Taken together, these results suggest that CYP
alterations are not merely the result of hepatotoxicity aris-
ing from transgene product accumulation or overwhelm-
ing viral gene expression.
In an effort to identify a potential mechanism by which
Ad infection alters CYP expression and function, we first
chose to examine changes in expression of the pregnane ×
receptor (PXR). Transcription of CYP3A2 is thought to
occur by heterodimerization of two orphan nuclear recep-
tors, PXR and the retinoid × receptor alpha (RXRα) [19].
RXRα is a nuclear receptor that forms complexes with
many other molecules to regulate gene transcription,
whereas PXR has been often referred to as the "master"
regulator of CYP3A [18,26-28]. PXR levels were signifi-
cantly suppressed 24 hours after administration of all
active recombinant viruses but recovered to baseline lev-
els in all groups except those given wild type virus (Figure
9, p ≤ 0.05). Given that CYP3A2 continued to be sup-
pressed in all groups given active virus beyond 24 hours,
we believe that changes in CYP3A2 expression and func-
tion may not be mediated by changes in PXR during ade-
novirus infection. This is further supported by another
study in which it was reported that CYP was significantly
suppressed in PXR knockout mice after treatment with
bacterial endotoxin [29].
Although no appreciable changes in PXR and RXR mRNA
levels were detected after administration of any of the vec-
tors studied, post-translational modifications of these
proteins and CYP itself such as phosphorylation, ubiqui-
tination and redistribution between the nucleus and cyto-
plasm in response to virus-induced cell signaling cascades
could account for the observed reduction in CYP during
adenovirus infection and would not be readily detectable
by the techniques used to assess changes in CYP, RXR and
PXR described in this manuscript [30-32]. The possibility
that these modifications are occurring and, in turn,
impacting CYP expression and function is highlighted by
the fact that administration of the UVAd vector signifi-
cantly suppressed enzyme activity as early as six hours, an
effect that lasted for 14 days in the case of CYP3A2 (Figure
2). This profound post-translational effect that a geneti-
cally inactive yet intact virus had on each CYP isoform
may be the direct result of interaction of capsid proteins
with virus receptors and subsequent internalization of
virus particles at the cellular level. Binding of the fiber pro-
tein to the primary adenovirus receptor, the Coxsackievi-
rus and Adenovirus receptor (CAR), facilitates interactions
between penton base proteins and cell surface integrins
promoting virus internalization [33]. Engagement of
integrin receptors during this process initiates several sig-
nal transduction pathways such as extracellular-signal-
regulated kinase (ERK), phophatidylinositol 3-kinase
(PI3K) and protein kinases A and C (PKA and PKC) which
may contribute to the observed changes in CYP after
administration of any of the vectors included in this study
[34-36]. Data from in vitro studies and microarray analysis
of hepatic tissue provide further support that notion that
engagement of integrin receptors, common points of
entry for many pathogenic organisms [37], is sufficient to
initiate changes in CYP3A2. Treatment of primary hepato-
cytes with a peptide known to block integrin receptors
and prevent adenoviral infection significantly reduced
CYP3A2 activity with respect to untreated controls (Figure
10).
Microarray analysis of hepatic tissue samples (oligo GEAr-
ray Rat Signal Transduction Pathway Finder microarrays;
SuperArray, Frederick, MD) revealed that administration
of each of the viruses significantly altered gene expression
patterns associated with several key signal transduction
pathways (data not shown). Expression of genes associ-
ated with the PI3K, PKC and nuclear factor kappa B
(NFKB) pathways were induced with respect to those
found in saline treated animals on average by a factor of
3.8, 4 and 4.6 respectively by each of the viruses included
in this study. These pathways are of particular interest in
the context of explaining our findings with respect to PXR
and RXR expression. Ding and Staudinger described an
increase in PXR activity in the presence of compounds that
induced protein kinase A in vitro [38]. They subsequently
found via a reporter gene assay that PXR activity was sig-
nificantly suppressed after treatment with compounds
that induced protein kinase C [39]. If this is the case in
vivo, we believe that adenovirus infection did not signifi-
cantly affect PXR levels because both PKA and PKC are
upregulated during adenovirus infection [33,34], keepingVirology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
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the expression of this protein in check except at the 24
hour time point when the balance between the expression
of each enzyme might be disrupted since they are each
uniquely involved at different stages of virus internaliza-
tion and trafficking to the nucleus which occur during this
timeframe [34]. It has also been shown that activation of
c-Jun N-terminal kinase (JNK), a kinase downstream of
PKC [40], induces phosphorylation of RXRα [41,42],
which causes it to redistribute from the nucleus to the
cytoplasm, preventing it from forming the heterodimer
complex with PXR and suppressing CYP expression and
function [43]. Microarray data also suggests that changes
in CYP after adenovirus infection may be in response to
products associated with the NFKB pathway. The small
heterodimer partner (SHP), an orphan nuclear receptor
specifically expressed in the liver and a limited number of
other tissues, is a transcriptional co-activator of NFKB and
is also activated by JNK [44,45]. SHP can bind to both
PXR and RXRα preventing heterodimer formation neces-
sary for CYP expression [43,46-48]. To date an increase in
SHP expression during adenovirus expression has not
been described. Additional studies assessing the level of
SHP in the liver during adenovirus infection, distribution
patterns and phosphorylation status of PXR and RXRα in
vitro and in vivo will further support these hypotheses and
are currently underway in our laboratory.
Materials and methods
Materials
The following were purchased from Sigma-Aldrich (St.
Louis, MO): phosphate-buffered saline (PBS), L-lysine,
riboflavin, polyoxyethylene-sorbitan monolaurate
(Tween 20), dimethylsulfoxide (DMSO), ethylenediami-
netetraacetic acid (EDTA), formaldehyde, isopropanol,
glucose-6-phosphate,  β-nicotinamide adenine dinucle-
otide phosphate sodium salt (NADP+) and 11α-hydroxy-
progesterone. Protogel® acrylamide was purchased from
National Diagnostics (Atlanta, GA). 5-bromo-4-chloro-3-
indolyl-β-D-galactoside (X-gal) was purchased from Gold
Biotechnology (St. Louis, MO). Polyclonal rat CYP3A2
and CYP2C11 primary antibodies were from BD Gentest
(Woburn, MA). Corresponding horseradish peroxidase-
conjugated secondary antibodies were from ICN Pharma-
ceuticals, Inc. (Aurora, OH). Isoform-specific CYP protein
standards were from XenoTech, LLC (Lenexa, KS). PCR
primers were purchased from Sigma-Genosys (The Wood-
lands, TX). Unless noted otherwise, all other materials
were purchased in the highest purity from EMD Chemi-
cals (Gibbstown, NJ).
Adenovirus Production
WT (VR-5, ATCC, Manassas, VA) and first generation
recombinant adenovirus 5 expressing the E. coli beta-
galactosidase transgene under the control of a CMV pro-
moter (AdlacZ) were amplified in 293 cells. Helper-
dependent adenovirus 5 (HDAd) was prepared using the
HD-Ad-SRα-β GEO vector containing a fusion gene of the
E. coli beta-galactosidase transgene and the neomycin
resistance gene under the control of the SRα promoter in
293Cre cells as described [49]. Amplification and rescue
of the vector was achieved with the use of the AdLC8cLuc
helper virus. Both vectors were purified from cell lysates
by banding twice on cesium chloride gradients. AdlacZ
was desalted on an Econo-Pac 10DG disposable chroma-
tography column (BioRad, Hercules, CA) equilibrated
with phosphate buffered saline, pH 7.4. HDAd was
desalted by dialysis overnight in the same buffer. Contam-
ination of helper virus was determined in the laboratory
of Dr. Lucio Pastore, Federico II University, according to
established techniques [50]. Positive fractions were col-
lected and the number of virus particles (active and inac-
tive) determined using the method of Maizel et al. with
the following formula [51]:
Engagement of Integrin Receptors with a Non-Infectious Pep- tide Suppresses CYP3A2 in Primary Rat Hepatocytes Figure 10
Engagement of Integrin Receptors with a Non-Infec-
tious Peptide Suppresses CYP3A2 in Primary Rat 
Hepatocytes. Treatment with a peptide rich in RGD 
sequences at a concentration known to reduce adenovirus 
transduction by over 80% in culture (1.5 mg/ml, [58]) 
reduced CYP3A2 activity in primary hepatocytes by 60%. A 
peptide that differed by only one amino acid residue at the 
same concentration (RGE, 1.5 mg/ml) that does not block/
engage integrin receptors did not affect CYP activity. Cells 
were also treated with bacterial lipopolysaccharide (LPS, 10 
μg/ml) and cyclosporine A (CsA, 5 μg/ml), compounds that 
also suppress CYP3A2 [59,60], to confirm our results. Values 
are presented as the mean ± standard error of 3 replicates 
for each treatment group. Statistical significance was deter-
mined between individual treatment groups and vehicle con-
trols by one-way analysis of variance with a Bonferroni/Dunn 
post-hoc test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.Virology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
Page 14 of 17
(page number not for citation purposes)
Virus particles/ml = (absorbance at 260 nm) × (dilution 
factor) × 1.1 × 1012
All animals were treated with freshly purified virus.
PEGylation of Adenovirus
Adenovirus expressing beta-galactosidase was prepared as
described above. Protein content of the preparation was
determined using BioRad DC Protein Assay reagents and
bovine serum albumin as a standard in a microplate for-
mat. Ten micrograms of monomethoxypoly(ethylene)
glycol, activated by tresyl chloride (Sigma Aldrich), was
added for each microgram of protein present [52]. The
coupling reaction was performed at 25°C with gentle agi-
tation. The reaction was stopped by the addition of L-
lysine, in a 10-fold excess with respect to the amount of
PEG added. Unreacted PEG, excess L-lysine, and reaction
byproducts were removed by buffer exchange over an
Econo-Pac 10DG disposable chromatography column
equilibrated with 100 mM potassium phosphate-buffered
saline (pH 7.4).
Riboflavin-Mediated Inactivation of Recombinant 
Adenovirus
Recombinant adenovirus 5 expressing beta-galactosidase
was inactivated by a method unique to our laboratory as
described [53]. A sufficient amount of riboflavin stock
solution (1665 μM in DMSO) was added to purified virus
to yield a final concentration of 50 μM. The virus/ribofla-
vin mixture was placed in a 100 mm polystyrene dish
(Fisher Scientific, Pittsburgh, PA) surrounded by ice and
"sandwiched" between two UV light sources (Ultra-Lum,
Claremont, CA and UVP, Upland, CA) each emitting UV
light (365 nm, 1000 μW/cm2) for 45 minutes. Virus inac-
tivation was confirmed by serial dilution of samples and
infection of HeLa cells as described [53].
Administration of Recombinant Adenovirus
All procedures were approved by the Institutional Animal
Care and Use Committee of The University of Texas at
Austin and are in accordance with the guidelines estab-
lished by the National Institutes of Health for the humane
treatment of animals. Male Sprague-Dawley rats (9–10
weeks old, Harlan Sprague Dawley, Inc. (Indianapolis,
IN) were housed in individual cages and allowed unre-
strained access to standard rodent chow (Harlan Teklad,
Indianapolis, IN) and tap water. A single intra-muscular
injection of a 1:1:1 (v/v/v) ratio of ketamine (100 mg/ml,
Wyeth, Fort Dodge, Animal Health, Overland Park, KS),
xylazine (20 mg/ml, Sigma Aldrich), and acetopromazine
(10 mg/ml, Sigma Aldrich) achieved deep plane anesthe-
sia for placement of catheters into the right jugular vein.
Twenty-four hours after surgery, rats were given a single
intravenous dose of 5.7 × 1012 viral particles per kilogram
(vp/kg) in a 0.5 ml volume of either: WT, AdlacZ, PEGAd,
UVAd, or vehicle, phosphate buffered saline. A separate
group was given 1.3 × 1012 vp/kg of the HDAd vector in
the same volume of saline. This dose was based upon the
typical yield for this virus in our laboratory. Upon sacri-
fice, serum was collected for assessment of alanine ami-
notransferase (ALT). A small section of liver was
immediately excised and stored in RNAlater™ (Qiagen,
Valencia, CA) at 4°C for microarray analysis. Additional
tissue was placed in Tissue-tek®  embedding medium
(Fisher Scientific, Pittsburgh, PA) for X-gal histochemistry.
Remaining tissue was excised, rinsed in saline, snap fro-
zen in liquid nitrogen, and stored at -80°C for microsome
preparation, and PCR.
Isolation of Primary Hepatocytes
Hepatocytes were isolated from adult male Sprague Daw-
ley rats (200–300 g) by a modified two step in situ colla-
genase perfusion protocol [54]. Cell isolates were further
purified on Percoll gradients and seeded at a density of 1.5
× 105 cells/cm2 onto rat tail collagen treated culture dishes
(BD Biosciences, Bedford, MA). Cells were maintained in
HepatoZYME-SFM (Invitrogen, Carlsbad, CA), supple-
mented with 1% L-glutamine (Hyclone, Logan, UT), gen-
tamycin (0.5 μg/ml, Cambrex Biosciences, Walkersville,
MD) and penicillin (100 U/ml)/streptomycin (100 μg/
ml) (Mediatech, Herndon, VA).
Microsome Isolation
Hepatic microsomal proteins were isolated by differential
centrifugation as described previously [9]. Microsomes
were stored at -80°C prior to analysis.
Gel Electrophoresis and Immunoblot Analysis
Microsomal proteins (20 μg) were separated by size by
sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS-PAGE) as described [9]. Detection of putative pro-
teins was achieved with a 1:3000 dilution of the specific
primary CYP antibody in 3% NFDM followed by a second
incubation with a corresponding horseradish peroxidase
conjugated secondary antibody (1:3000). Immune com-
plexes for CYP3A1/2 and CYP2C11 were detected by
chemiluminescence (Western Lightning detection kit,
PerkinElmer, Boston, MA). Protein band densities were
analyzed using Kodak 1D image analysis software (East-
man Kodak, Rochester, NY). CYP3A1 and CYP3A2 co-
migrate during electrophoresis. The antibody used to
detect CYP3A2 was polyclonal with cross reactivity to
CYP3A1, therefore all protein levels for CYP3A2 are
reported as CYP3A1/2.
In vitro Testosterone Hydroxylation Assay
Metabolic activity for CYP3A2 and 2C11 was determined
by  in vitro analysis of testosterone hydroxylation as
described [9]. Samples were incubated with testosterone
(Sigma Aldrich) for 18 minutes at 37°C with gentle agita-Virology Journal 2008, 5:111 http://www.virologyj.com/content/5/1/111
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tion after addition of glucose-6-phosphate dehydrogenase
(1 unit/μl, Sigma) and then quenched with dichlorometh-
ane (5 ml). 11α-hydroxyprogesterone (1.2 μg, Sigma) was
added as an internal standard. The organic phase was
evaporated under a constant stream of air, dissolved in
200 μl of methanol and stored in a sealed tube at 4°C
until analysis. Testosterone metabolites were separated
and quantified by HPLC according to a previously
described method [55]. Peak areas of corresponding
hydroxylation metabolites were measured and compared
to peak areas of the internal standard within the same run.
RT-PCR
Hepatic RNA was isolated with TRIzol (Invitrogen,
Carlsbad, CA) according to the manufacturer's instruc-
tions. Samples were stored at -80°C prior to analysis.
Hepatic RNA (1 μg) was generated using a reverse tran-
scription kit, RETROscript, (Ambion, Austin, TX) follow-
ing the manufacturer's instructions. PCR was performed
using ReadyMix PCR Reaction Mix (Sigma-Aldrich). Each
reaction (final reaction volume 12.5 μl) contained 0.5 μl
of reverse-transcription product, 0.1 mM of each primer
and 1 μl of QuantumRNA™ 18S internal standard
(Ambion, Austin, TX) at a primer:competimer ratio of 4:6
for CYP 3A2 and 2C11 and 3:7 for PXR and RXR reactions.
Gene-specific reaction conditions and primer sequences
are summarized in Table 1. Reaction products were visu-
alized on a 1.5% agarose gel containing ethidium bro-
mide and band intensity determined using Kodak 1D
image analysis software.
Liver function analysis
Serum ALT levels were measured with Vitros ALT slides on
a Vitros DT60 autoanalyzer (Ortho-Clinical Diagnostics,
Rochester, NY).
X-Gal histochemistry
Frozen liver sections (6 μm) were fixed in 0.5% glutaral-
dehyde and stained for beta-galactosidase activity as pre-
viously described [56].
Data analysis
One-way analysis of variance with a Bonferroni/Dunn
post-hoc analysis was used to determine statistical differ-
ences between individual groups (SuperANOVA, Abacus
Concepts, Berkley, CA). Differences were determined to
be significant when the probability of chance explaining
the results was reduced to less than 5% (p < 0.05).
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